LIDDS

An innovative drug delivery platform for the benefit of patients and pharma company

LIDDS AB (publ) develops injectable drugs for cancer and other diseases based on our unique proprietary NanoZolid technology. NanoZolid helps solve some of the main problems with the way drugs work in the body and which affect patient quality of life. NanoZolid enables the controlled, long-term and personalized release of drugs for up to six months. NanoZolid can be combined with traditional small molecules as well as with larger molecules.